Interpretation guidance for MHRA regulatory considerations for phage therapeutic products
Microbiology · 2025
DOI: 10.1099/mic.0.001613 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microbiology, 2025. Verfasst von Carmen Coxon und 13 weiteren Autor:innen. Beteiligte Einrichtung: MHRA Science Campus, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 EQG, UK. Hauptthemen laut MEDLINE: Bacteriophages, Phage Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Food Safety Research Network, BBSRC, UKHSA Grand in Aid.
Abstract (Originalsprache)
A corrigendum of this article has been published full details can be found at https://doi.org/10.1099/mic.0.001670 On 4 June 2025, the MHRA published ‘Regulatory considerations for therapeutic use of bacteriophages in the UK’. This was in response to recommendations made by the House of Commons Science, Innovation and Technology Committee Inquiry into the ‘The Antimicrobial Potential of Bacteriophages’. The MHRA Regulatory Considerations for phage therapeutic products (PTPs) outlines the relevant regulatory route and requirements to use PTPs as licensed or unlicensed medicines. While this guidance provides the necessary information, it is recognized that regulatory information can be inaccessible to academic and small- to medium-sized enterprise developers who are often unfamiliar with the language, terminology and location of such information. The MHRA, in consultation with the Innovate UK Phage Innovation Network, has therefore developed this interpretation to help PTP developers understand what the guidance is saying, and what evidence is required for regulatory assessment of a marketing authorization application. Examples have been included throughout to provide context and as an aid to understanding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- MHRA Science Campus, Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 EQG, UK.
- National Institute for Health and Care Excellence, Manchester, UK.
- Innovate UK Phage Innovation Network Advisory Group, Unit 218, Business Design Centre, 52 Upper Street, Islington, London N1 0QH, UK.
- Bacteriophages and Viromics, Quadram Institute, Rosalind Franklin Road, Norwich Research Park, Norwich NR4 7UQ, UK.
- NexaBiome, West of Scotland Science Park, Block 2 Kelvin Campus, 2317 Maryhill Road, Glasgow G20 0SP, UK.
- Aparon, Hill Farm Middleton Lane, Middleton, Tamworth, B78 2BN, UK.
Förderung
- Food Safety Research Network
- BBSRC
- UKHSA Grand in Aid
- NIHR
- Cystic Fibrosis Trust and LifeArc
Zitieren
APA
Coxon, C., Bell, E., Adriaenssens, E., Clark, J., Edwards, J., Gohir, T., Hodges, F., Jones, J., Rees, C., Sansom, A., Smith, D., Sutton, M., Trippett, C., & Turner, D. (2025). Interpretation guidance for MHRA regulatory considerations for phage therapeutic products. Microbiology. https://doi.org/10.1099/mic.0.001613
Vancouver
Coxon C, Bell E, Adriaenssens E, Clark J, Edwards J, Gohir T, et al. Interpretation guidance for MHRA regulatory considerations for phage therapeutic products. Microbiology. 2025. doi:10.1099/mic.0.001613
BibTeX
@article{Coxon2025,
author = {Coxon, Carmen and Bell, Elizabeth and Adriaenssens, Evelien and Clark, Jason and Edwards, Joe and Gohir, Tas and Hodges, Francesca and Jones, Josh and Rees, Cath and Sansom, Annette and Smith, Darren and Sutton, Mark and Trippett, Clare and Turner, Dann},
title = {Interpretation guidance for MHRA regulatory considerations for phage therapeutic products},
journal = {Microbiology},
year = {2025},
doi = {10.1099/mic.0.001613}
}
EUVIMED